Sara McGahan is a Manager at CBPartners working across a variety of practices to address a range of commercial business issues.
Connect with Sara McGahan
Basic science has been redeployed to establish a new understanding of Alzheimer's Disease, focusing on novel biomarkers and cutting-edge therapeutic approaches to slow or reverse disease progression, where the amyloid beta theory has otherwise failed
Since its founding in 2006, ICER has become an influential organization in the drug pricing and US healthcare landscape. ICER reports have been increasingly leveraged by payer organizations in coverage decisions; further, pharma has increasingly engaged with ICER when launching a product or announcing a new drug price. CBPartners US Center of Excellence explores whether ICER and pharmaceutical manufacturers are allies or adversaries.
Changes to IRP policies in the CEE markets can impact pricing across the EU region and should therefore be closely monitored particularly as the list price in a given CEE market may be re-referenced by other global markets.
PART I of CBPartners' CNS series: as the scientific and regulatory barriers in Parkinson’s disease are beginning to be addressed, biotechnology firms are developing innovative therapies based on academic studies showing potential therapeutic targets and pathways, which have been generated with increasing quantity over the past few years using genetic and pre-clinical studies.
PART I of CBPartners' CNS series: the concept of external investment may represent a positive trend in the neuroscience space where different size firms are focused on their comparative strengths.
PART II of CBPartners' CNS series: